# A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas

> **NCT00179751** · PHASE1,PHASE2 · TERMINATED · sponsor: **Celgene Corporation** · enrollment: 50 (—)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** CC-5013
- **DRUG:** gemcitabine

## Key facts

- **NCT ID:** NCT00179751
- **Lead sponsor:** Celgene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-04
- **Primary completion:** —
- **Final completion:** 2006-08
- **Target enrollment:** 50 (—)
- **Last updated:** 2005-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00179751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00179751, "A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00179751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*